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Background: Moringa stenopetala (Baker f.) Cufod. is a medicinal plant that has been
used in Ethiopian traditional medicine as a remedy for treatment of hypertension and
diabetes. The aim of this study was to evaluate antihypertensive and antihyperlipidemic
effect in fructose induced hypertensive rats.
Methods: Rats were randomly divided into control and treatment groups (n = 6).
Treatment groups were given daily extracts (250, 500, and 1000mg/kg) orally with
fructose. Whereas, positive, negative and normal control groups were received captopril
(20mg/kg/day with fructose), only fructose (66% w/v ad libitum) and distilled water ad
libitum for 15 days, respectively. The blood pressure was measured every 5th day using
tail cuff blood pressure analyzer, and on the 16th day the blood was sampled to evaluate
antihyperlipidemic effect using clinical chemistry analyzer.
Results: The study showed that aqueous and 70% ethanol extracts significantly
prevented blood pressure increment in a dose dependent manner comparable to that of
the standard drug. Similarly, the extracts suppressed increment in lipid profile (cholesterol,
glucose, and triglycerides) comparedwith negative control. The biochemical test revealed
that extracts produced a rise in liver but no effect on kidney function indicators compared
with normal control.
Conclusion: These findings revealed that both crude extracts of M. stenopetala
(Baker f.) Cufod. possess antihypertensive and antihyperlipidemic effect.
Keywords: antihypertensive, fructose, in vivo, Moringa stenopetala, antihyperlipidemic
Abbreviations: CVD, Cardiovascular Disease; EPHI, Ethiopian Public Health Institute; EtOH, Ethanol; AQ, Aqueous; EtAc,
Ethyl acetate; BP, Blood pressure; BP0, Basal blood pressure; SBP, Systolic blood pressure; MAP, Mean arterial blood pressure;
DBP, Diastolic blood pressure; TC, Total cholesterol; BG, Blood glucose; TG, Triglyceride; D5, Fifth day; D10, Tenth day;
D15, Fifteenth day; STZ, Streptozocin; ACEIs, Angiotensin Converting Enzyme Inhibitors; ARBs, Angiotensin II Receptor
Blockers; CCBs, Calcium Channel Blockers.
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INTRODUCTION
Hypertension is a leading cause of CVDs such as myocardial
infarction and stroke worldwide. The proportion of the global
burden of disease attributable to hypertension has significantly
increased from about 4.5% (nearly1 billion adults) in 2000, to
7% in 2010 (WHO, 2008; AU, 2013). Hypertension leads to
complications with considerable morbidity and mortality which
is responsible for at least 45% of deaths due to heart disease
and 51% of deaths due to stroke (WHO, 2008). Hypertension
accounts for 9.4 million deaths worldwide every year. At the
beginning of the twentieth century, CVD was responsible for
less than 10% of all deaths worldwide, but by 2008, the figure
had risen to 30%. The number of people with the condition rose
from 600 million in 1980 to 1 billion in 2008 (WHO, 2011).
Moreover, the number of people with uncontrolled hypertension
has increased to around 1 billion worldwide in the past three
decades (Danaei et al., 2011). About 80% of the global burden
of CV death occurs in low and middle income countries. This
is nearly as many deaths as caused by HIV, malaria, and TB
(Gaziano et al., 2006; Lopez et al., 2006). This makes hypertension
the single most important cause of morbidity and mortality
globally and highlights the urgent need of action to address the
problem (AU, 2013). Hypertension was almost non-existent in
African adult societies in the first half of the twentieth century,
the prevalence increased significantly over the past two to three
decades to more than 40% (about 80 million) and projections
based on current epidemiological data suggest that this figure
will rise to 150 million by 2025 (AU, 2013). WHO projects that
over the next 10 years Africa will experience the largest increase
in death rates from CVD and therefore the negative economic
impact of CVD will be more felt on the continent (Alwan, 2011).
There are different models of inducing hypertension
in animals. Such as, renovascular hypertension, dietary
hypertension, endocrine hypertension, neurogenic hypertension,
psychogenic hypertension, genetic hypertension, and other
models (Kaur et al., 2011). Among these, the dietary induction
of hypertension is the most commonly employed in rodents and
the mechanism behind is described below (Figure 1; Abdulla
et al., 2011). Increases in dietary carbohydrate intake such as
fructose, sucrose, or glucose can raise BP in normal rats (Hwang
et al., 1987). High fructose consumption will produce a model of
the metabolic syndrome with hypertension, insulin resistance,
hyperinsulinemia, hyperlipidemia, and hypertriglyceridemia in
normal rats and this greatly accelerates progression of chronic
kidney disease (Gersch et al., 2007).
Clinically, various antihypertensive drugs such as ACEIs,
ARBs, diuretics, CCBs, β blockers, alpha-1 blockers, central
α-2 agonists, non-selective α and β blockers, and direct
vasodilators have been used to manage hypertension and
to alleviate symptoms (Benowitz, 2012). ACEIs and ARBs
are ideal first line antihypertensive agents in individuals
with type 2 diabetes (Tashko and Gabbay, 2010). Despite
the availability of a wide range of antihypertensive drugs,
hypertension and its complications are still important causes of
morbidity and mortality in Africa. More than 50% of treated
hypertensive patients have a BP level greater than 140/90mm
Hg (uncontrolled hypertension; Salako et al., 2003). Moreover,
the efficacy of these drugs are only 40–60%, and usually two
or more antihypertensive drugs from different categories need
becombined to achieve optimal results, however side effects from
these medications are important concerns (Du and Chen, 2005).
Various herbal preparations have been claimed to have benefit
for hypertension. Moringa stenopetala (Baker f.) Cufod. is one
of those plants used in Ethiopia. It grows abundantly in south
western Ethiopia at an altitude range of 1000–1800m where the
leaves are eaten as vegetable besides its medicinal use (Arora et al.,
2013). The species is known by different vernacular names such
as “Shiferaw” in Amharic, “Aleko” in Gamugna, and “Cabbage
tree” in English (Mekonnen and Gessesse, 1998). It has been
reported that, M. stenopetala (Baker f.) Cufod. has hypotensive
(Mengistu et al., 2012), antihyperglycemic (Toma et al., 2012,
2015; Sileshi et al., 2014) and also has a nutritional value (Abuye
et al., 2004). The objective of the present study is, therefore, to
investigate the antihypertensive and antihyperlipidemic effects of
extracts and fractions of M. stenopetala (Baker f.) Cufod. leaves
in fructose induced hypertensive rats.
MATERIALS AND METHODS
Drugs and Chemicals
Ethyl Acetate (lot no: 8114/4, Park Scientific Limited,
Northampton, UK), Absolute Ethanol (lot no: E35070/2,
WINLAB, UK), Lead Acetate (lot no: V9H4049, Celtic
Chemicals, South Wales, UK), Ammonia Solution (lot no:
9457, Scientific limited, UK), Dinitro-2-4- Phenylhydrazine
(lot no: 231523, VWR Prolabo chemicals, USA), Sulfuric Acid
(lot no: 8114/1, Scientific limited, UK), Chloroform (lot no:
8114/1, Scientific limited, UK), Hydrochloric Acid (lot no: 2571,
Parchem fine and specialty chemicals, UK), D-Fructose (lot
no: SL54161301, LobaChemie, India), Captopril (lot no: 48794,
EPSITRON Limited, Nicosia, Cyprus) were used in the study.
All the drugs, chemicals, and reagents used complied with the
required standard and were of analytical grade.
Instruments and Apparatus
Lyophilizer/ Freeze dry system (Labconco, 12 L Console Freeze
Dry 230v-60 (7754040), Freeze Dry System, USA), BP analyzer
(Model 179, USA), Centrifuge (Rotant 98, Hettich, Zentrifugen,
UK), Clinical chemistry analyzer (Cobas-e-411, HITACHI,
ROCHE, Germany).
Plant Material
The fresh M. stenopetala (Baker f.) Cufod. leaves were collected
from Southern Ethiopia around Arbaminch, about 500 km far
from Addis Ababa on September 2014. The plant material was
authenticated by a taxonomist in the EPHI and a voucher number
AL-001 was deposited in the herbarium for future reference.
Experimental Animals
A statement of ethics approval is obtained from Scientific and
Ethical Review Committee of EPHI. The experiments were
performed on adult, healthy male Wistar rats (Rattus norvegicus)
weighing 150–200 g bred and obtained from the EPHI. All the
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FIGURE 1 | The proposed mechanisms by which fructose feeding results in hypertension.
animals used for this study were kept in standard animal cages
and maintained under laboratory conditions of temperature (22
± 3◦C), relative humidity (40–70%) and 12 h day-12 h night
and had free access to food (standard pellet diet) and water
ad libitum. The animals were treated humanely throughout the
study period and were kept in a well-controlled area according
to the guideline for use and care of animals (National Research
Council, 2011).
Plant Material Preparation and Extraction
Fresh M. stenopetala leaves were garbled, chopped, dried
under shade (at room temperature), grinded to powder using
mortar and pestle and stored in cool and dry place. Weighed
amounts of 1.208 and 2.130 Kg powdered leaves were kept
in Erlenmeyer flasks and macerated with water (distilled and
deionized) and 70% ethanol at room temperature under a
rotator shaker until exhaustion for 4 and 72 h, respectively. The
70% EtOH extract was filtered using cotton gauze and then
with Whatman filter paper No.1. The filtrate was concentrated
under reduced pressure using Rota vapor. The semidried
residue was kept on a water bath at 40◦C overnight and
then with a Lyophilizer to completely remove the solvent
residue. The AQ crude extract was filtered using a Whatman
filter paper No.1, kept in refrigerator overnight to freeze and
lyophilized to remove the water. The total yield of the AQ
and 70% EtOH extract were calculated 17.1 and 4.9% (w/w),
respectively.
About 178.95 g of dried AQ crude extract were defatted
by petroleum ether and partitioned with EtAc, the solvent was
removed using Rota vapor and Lyophilizer to obtain EtAc (18.6%
w/w yield) and AQ residue (35% w/w yield), respectively. The
dried extracts were kept in a refrigerator until used for the
experiment.
Phytochemical Screening
All extracts used for the in vivo study were subjected to
phytochemical screening following methods described by Tiwari
et al. (2011). The extracts along with negative controls were tested
for the presence of alkaloids, saponins, polyphenols, flavonoids,
coumarins, terpenoids, anthraquinones, tannins, phytosterols,
and glycosides as follows:
a) Alkaloids
One and half milliliter of 10% HCl was added to 0.5mg of
the extracts in a test tube. The mixture was heated for 20min.
It was then cooled and filtered. To 1ml of the filtrate five drops
Mayers and Draggendorff ’s reagents each were added. Formation
of cream and orange colored precipitates respectively indicates
the presence of alkaloids in the extracts.
b) Saponins
Froth test: An aqueous solution of 0.5mg of the extract in a
test tube was vigorously shaken for 2min. Foam which persisted
for 30min and doesn’t disappear upon warming was taken as an
indication of the presence of saponin in the extract.
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c) Polyphenols (Phenolic compounds)
Three drops of a mixture of 1ml 1% FeCl3 and 1% K3Fe(CN)6
each were added to 2ml of extracts. Formation of green or blue
color was taken as an indication of the presence of polyphenols.
d) Flavonoids
To 2ml of aqueous solution of the extract four drops of 2%
lead acetate solution was added. Development of yellow or orange
color confirms the presence of flavonoids.
e) Coumarins
Two milliliter of 10% ammonia solution was added to 5ml
concentrated alcoholic solution of the extracts. The occurrence of
an intensive fluorescence under UV light indicates the presence
of coumarin derivatives.
f) Terpenoids (Ketonic)
One milliliter of 2, 4-dinitrophenylhydrazine solutions (0.5 g
dissolved in 100ml of 2M HCl) was added to 2ml aqueous
solution of the extract. Formation of yellow-orange coloration
indicates the presence of a ketonic terpenoids.
g) Anthraquinones
Borntrager’s test: Five milliliter of the extract was dried and
shaken with 3ml petroleum ether. The filtrate was added to
2ml of a 25% ammonia solution. The mixture was shaken and
formation of a red coloration was taken as an indication of the
presence of free anthraquinones.
h) Tannins
Three drops of 5% ferric chloride solution was added to 1ml
of the extract solution in water. A greenish or blue coloration or
precipitation was taken as indication of the presence of tannins.
i) Phytosterols and Withanoids
Five drops of 3% vanillin in conc. H2SO4 was added to a
concentrated chloroform solution of extracts. Formation of a
rose or reddish brown color indicates the presence of anoids or
phytosterols.
j) Test for Glycosides (Keller-Killiani Test)
To 0.5 g of each extract suspended in 5ml water, 2ml of glacial
acetic acid containing one drop of ferric chloride hexahydrate
(FeCl3.6H2O) solution was added. This was mixed with 1ml of
concentrated sulfuric acid and observed for a brown ring at the
interface or a violet ring below the brown ring; alternatively acetic
acid was added and observed for a greenish ring above the brown
ring which gradually spread throughout this layer.
Evaluation of In vivo Antihypertensive
Effect
Among different models available, for the present study, the
dietary induction of hypertension in male Wistar rats was
employed using 66% w/v D-Fructose according to methods
described by Jena et al. (2013). TA
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TABLE 2 | Effect of crude extracts and solvent fractions ofM. stenopetala (Baker f.) Cufod. leaves on SBP in D-Fructose (66% w/v ad libitum) induced rats.
Substance administered Dose (mg/kg) SBP
D1 (mmHg) D5 (mmHg) D10 (mmHg) D15 (mmHg)
D-Fructose 66% w/v ad libitum 113.50 ± 1.52 132.67 ± 0.71***c,*c 144.33 ± 1.33***c,*c 163.67 ± 1.12***c,*c
Captopril 20 113.83 ± 2.12 124.83 ± 1.19**c,*c 120.67 ± 0.88**c,*a 120.50 ±0.76**c
AQ crude 250 114.17 ± 1.40 129.50 ± 1.38*c 138.67 ± 0.88**c,***c,*c 149.67 ± 1.28**c,***c,*c
500 112.50 ± 1.20 126.83 ± 0.95**b,*c 132.17 ± 0.70**c,***c,*c 136.50 ± 0.76**c,***c,*c
1000 116.83 ± 1.78 121.83 ± 0.60**c 123.00 ± 0.58**c 124.67 ± 0.88**c,***a,*b
70% EtOH crude 250 116.17 ±1.01 138.67 ± 0.88**b,***c,*c 146.83 ± 0.60***c, *c 157.17 ± 0.95**c,***c,*c
500 114.83 ± 1.96 130.50 ± 0.76***a,*c 137.50 ± 0.76**c,***c,*c 142.50 ± 0.76**c,***c,*c
1000 115.17 ± 1.97 119.00 ± 1.39**c,***b 124.33 ± 0.49**c,*c 133.50 ± 0.76**c,***c,*c
EtAc fraction of AQ crude 250 118.33 ± 0.88 141.33 ± 0.80**c,***c,*c 151.17 ± 0.60**c,***c,*c 161.17 ± 0.60***c,*c
500 119.67 ± 0.88 134.17 ± 0.70***c,*c 141.17 ±0.48***c,*c 151.50 ± 0.76**c,***c,*c
1000 116.50 ±1.48 124.33 ± 1.33**c,*a 134.50 ± 0.76**c,***c,*c 145.33 ± 0.88**c,***c,*c
AQ residue of AQ crude 250 116.83 ± 1.78 137.83 ± 0.60**a,***c,*c 142.17 ± 0.70***c,*c 156.00 ± 0.58**c,***c,*c
500 116.83 ± 1.54 132.67 ± 0.88***c,*c 139.50 ± 0.42**b,***c,*c 146.17 ± 0.60**c,***c,*c
1000 117.33 ± 1.63 124.17 ± 1.01**c 131.17 ± 0.60**c,***c,*c 139.50 ± 0.43**c,***c,*c
Results are expressed as mean ± SEM (n = 6), *compared with normal control (baseline or basal value); **compared with negative control; ***compared with positive control.
aP < 0.05.
bP < 0.01.
cP < 0.001.
Each rat wastrained and acclimatized to the restrainer and
transducer, for about 15min each day before the experiment.
The rat was restrained in a low-stress environment and allowed
to enter the holder freely at least 10–15min prior to obtaining
BP measurements. The animal’s nose was made to protrude
through the front of the nose cone allowing for comfortable
breathing and the tail of the animal was fully extended
to exit through the rear hatch opening of the holder. The
rat was warmed but not heated using restrainer, the room
temperature was maintained about 32–35.4◦C, reduce stress
and the blood flow to the tail was enhanced to acquire
a BP signal. The rat never had its head bent sideways or
its body compressed against the back hatch. The animal’s
temperature wasmonitored throughout the experiment (Malkoff,
2005).
Male Wistar rats were randomly divided into groups with six
animals (n = 6). Normal control rats (Group 1) received distilled
water ad libitum only, negative control rats (Group 2) received
66%w/v D-Fructose ad libitum only, positive control rats (Group
3) received captopril (20mg/kg/day) with 66% w/v D-Fructose
ad libitum and treatment rats, Group 4 received 250mg/kg
AQ crude extract, Group 5 received 500mg/kg AQ crude
extract, Group 6 received 1000mg/kg AQ crude extract, Group
7 received 250mg/kg 70%EtOH crude extract, Group 8 received
500mg/kg 70%EtOH crude extract, Group 9 received 1000mg/kg
70%EtOH crude extract, Group 10 received 250mg/kg AQ
residue of AQ crude extract, Group 11 received 500mg/kg AQ
residue of AQ crude extract, Group 12 received 1000mg/kg
AQ residue of AQ crude extract, Group 13 received 250mg/kg
EtAc fraction of AQ crude extract, Group 14 received 500mg/kg
EtAc fraction of AQ crude extract, Group 15 received 100mg/kg
EtAc fraction of AQ crude extract with 66% w/v D-Fructose
ad libitum for 15 days. The dose was selected based on the
acute toxicity study; LD50 was greater than 5000mg/kg (Geleta
et al., 2016). The extracts were prepared for administration by
weighing a required amount of dried extracts and dissolving
in a suitable vehicle (distilled water). Then, the uniformly
dissolved volume of extract was administered to rats using oral
gavage.
SBP and MAP were measured on the 1st day of experiment
before being induced using (66%w/v) D-Fructose, and was stated
as a BP0. Rats with SBP0 ≤ 120mmHg, MAP0 ≤ 100mmHg
and DBP0 ≤ 91mmHg were considered normotensive and were
given (66% w/v) D-Fructose ad libitum except those served as
normal control. Then BP was measured every 5th days to have
D5, D10 and D15 BP readings using BP analyzer. The SBP and
MAP were read from the pulse tracings and DBP was calculated
using formula –1.
DBP = (3MBP− SBP)/2 . . . . . . . . . . . . . . . . . . .1
Every measurement was taken in triplicate and the average value
was reported.
On the 16th day, the blood was collected in vacutainer
tube by cardiac puncture from night fasted cervical dislocated
rats. The serum was separated after centrifugation at 3000 rpm
for 10min. The serum lipid profile (TC, BG, TG) were
assayed using methods described by the manufacturer (Roche
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TABLE 3 | Effect of crude extracts and solvent fractions of M. stenopetala (Baker f.) Cufod. leaves on MAP in D-Fructose (66% w/v ad libitum) induced
rats.
Substance administered Dose (mg/kg) MAP
D1 (mmHg) D5 (mmHg) D10 (mmHg) D15 (mmHg)
D-Fructose 66% w/v ad libitum 96.95 ± 1.00 108.02 ± 0.80***c,*c 118.45 ±0.68***c,*c 130.88 ±0.50***c,*c
Captopril 20 97.40 ± 0.81 100.83 ± 0.99**c 99.55 ±0.74**c 99.38 ± 065**c
AQ crude 250 97.07 ± 0.75 106.83 ± 0.99***c,*c 112.88 ± 0.76**c,***c,*c 121.35 ±0.74**c,***c,*c
500 97.17 ± 0.59 103.15 ± 0.50**c,*c 105.05 ± 0.43**c,***c,*c 107.27 ± 0.84**c,***c,*c
1000 99.38 ± 0.68 101.27 ±0.58**c 100.23 ± 0.37**c 98.57 ± 0.75**c
70% EtOH crude 250 98.27 ± 0.44 110.45 ±0.58***c,*c 117.73 ± 0.56, ***c,*c 125.40 ± 0.48**c,***c,*c
500 97.28 ± 0.71 106.15 ± 0.48***c,*c 111.72 ± 0.63**c,***c,*c 113.62 ± 0.34**c,***c,*c
1000 98.72 ± 0.79 100.68 ±0.81**c,*c 101.68 ± 0.53**c 106.18 ± 0.55**c,***c,*c
EtAc fraction of AQ crude 250 99.77 ±0.43 111.70 ± 0.37**a,***c,*c 119.15 ± 0.85***c,*c 128.15 ± 0.51***c,*c
500 99.55 ± 0.75 108.17 ± 0.49***c,*c 114.50 ± 0.52**b,***c,*c 123.27 ± 0.32**c,***c,*c
1000 99.15 ± 0.70 105.00 ± 0.76***b,*c 112.50 ± 0.61**c,***c,*c 119.67 ± 0.44**c,***c,*c
AQ residue of AQ crude 250 99.17 ± 1.64 109.62 ± 0.56***c,*c 115.83 ± 0.69***c,*c 125.33 ± 0.47**c,***c,*c
500 97.95 ±0.83 108.12 ± 0.57*c 113.27 ±0.48**c,***c,*c 120.28 ±0.42**c,***c,*c
1000 98.80 ± 0.89 103.38 ±0.57**b,*a 108.03 ± 0.49**c,***c,*c 113.48 ±0.47**c,***c,*c
Results are expressed as mean ± SEM (n = 6), *compared with normal control; **compared with negative control; ***compared with positive control.
aP < 0.05.
bP < 0.01.
cP < 0.001.
diagnostics, Germany) using COBA-e-411 Clinical chemistry
analyzer instrument.
Statistical Analysis
All experimental data’s were expressed as mean values
(measurement of BP or % relaxation) ± S.E.M and were
subjected to biostatistical interpretation by SPSS windows
version 20 statistical packages all the way through a one-way
ANOVA followed by post-hoc test (Tukey Test) for multiple
comparisons of the mean differences and responses of different
drugs and extracts. Statistical significance of P < 0.05 were
considered as level of significance.
RESULTS
Phytochemical Screening
Basic investigations of the extracts for their major
phytocompounds is vital as the active principles of many
drugs are these secondary metabolites found in plants. The
various phytochemical screening tests performed on the crude
extracts and solvent fractions M. stenopetala leaves revealed the
presence of different secondary metabolites (Table 1).
In vivo Antihypertensive and
Antihyperlipidemic Activity
Effect on Blood Pressure
The negative control showed significant increase in SBP, MAP,
and DBP compared with normal control (P < 0.001) and
positive control (P < 0.001) in the D5, D10, and D15 of the
experiment (Tables 2–4). Those groups that received daily oral
administration of 1000mg/kg of AQ crude, 70% EtOH crude and
AQ residue of AQ extract prevented a rise in SBP and did not
show significant difference in the D5 of the experiment. In the
D10 of experiment, 1000mg/kg/day oral administration of the
crude extracts prevented a rise in SBP, did not show significant
difference in SBP compared with normal and positive control.
After consecutive oral daily administration for 15 days, all
treatment groups showed significant increase in SBP compared
with normal control (P < 0.01) and positive control (P < 0.05;
Table 2).
Groups that received, 1000mg/kg/day oral administration of
all extracts except the one that received AQ extract showed
significant increase (P < 0.001) in MAP compared with
normal control in the D5 of the experiment. In the D10 of
experiment, daily oral administration of 1000mg/kg of crude
extracts prevented a rise in MAP in a similar manner with
positive control. After consecutive oral daily administration for
15 days, group that received 1000mg/kg of AQ crude extract
didn’t show significant difference inMAP compared with normal
control as well as positive control (Table 3).
Daily oral administration of 500 and 1000mg/kg/day of AQ
crude, 70% EtOH crude, and AQ residue of AQ crude extracts
prevented a rise in DBP compared with normal control in
the D5 of the experiment. Groups that received AQ crude
extract (500 and 1000mg/kg/day) and 70% EtOH crude extract
(1000mg/kg/day) prevented a rise in DBP when compared with
normal control in the D10 of the experiment. After consecutive
oral daily administration for 15 days, groups that received
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TABLE 4 | Effect of crude extracts and solvent fractions of M. stenopetala (Baker f.) Cufod. leaves on DBP in D-Fructose (66% w/v ad libitum) induced
rats.
Substance Administered Dose (mg/kg) DBP
D1 (mmHg) D5 (mmHg) D10 (mmHg) D15 (mmHg)
D-Fructose 66% w/v ad libitum 88.67 ±1.36 95.67 ± 0.88***c,*c 105.50 ± 0.76***c,*c 114.50 ± 0.76***c,*c
Captopril 20 89.17 ± 0.87 88.83 ± 1.01**c 89.00 ± 0.97**c 88.83 ±0.95**c
AQ crude 250 88.50 ±0.76 95.50 ± 0.99***c,*c 100.00 ± 0.97**c,***c,*c 107.17 ± 0.60**c,***c,*c
500 89.50 ± 0.76 91.33 ± 0.67**a 91.50 ±0.76**c 92.67 ± 1.45**c,***a
1000 90.67 ±0.67 91.00 ± 0.58**b 88.83 ±0.31**c 85.50 ± 0.76**c,*a
70% EtOH crude 250 89.33 ± 1.05 96.33 ± 0.88***c,*c 103.17 ± 0.60***c,*c 109.50 ± 0.43**c,***c,*c
500 88.50 ± 0.76 94.00 ±0.58***b,*b 98.83 ± 0.60**c,***c,*c 99.17 ± 0.60**c,***c,*c
1000 90.50 ±0.76 91.50 ± 0.76**a 90.33 ± 0.88**c 92.5 ±0.76**c
EtAc fraction of AQ crude 250 90.50 ±0.76 96. 83 ± 0.60***c,*c 103.17 ± 1.08***c,*c 111.67 ± 0.67***c,*c
500 89.50 ±0.76 95.17 ± 0.60***c,*b 101.17 ± 0.60**a,***c,*c 109.17 ± 0.60**c,***c,*c
1000 90.50 ± 0.76 95.33 ± 0.88***c,*a 101.50 ± 0.76**a,***c,*a 106.83 ± 0.60**c,***c,*c
AQ residue of AQ crude 250 90.33 ± 1.80 95.50 ± 0.76**c,***c,*b 102.67 ± 0.88***c,*c 110.00 ± 0.58**b,***c,*c
500 88.50 ± 0.76 95.83 ± 0.79***c,*c 100.17 ± 0.79**b,***c,*c 107.33 ± 0.49**c,***c,*c
1000 89.50 ± 0.76 93.00 ± 0.82***a 96.50 ±0.76**c,***c,*c 100.50 ±0.76**c,***c,*c
Results are expressed as mean ± SEM (n = 6), *compared to normal control; **compared to negative control; ***compared to positive control.
aP < 0.05.
bP < 0.01.
cP < 0.001.
1000mg/kg AQ crude extract showed significant decrease (P <
0.05) in DBP compared with normal control (Table 4).
Effect on Total Cholesterol, Glucose, and Triglyceride
Plasma Levels
The negative control showed significant increase in serum TC
(P < 0.01), BG (P < 0.001) and TG (P < 0.001) level
compared with normal control. Although all extracts prevented
a rise in TG level in a dose dependent manner, there was
significant increase (P < 0.001) compared with normal control.
However, groups that received 500 and 1000mg/kg/day of all
extracts showed significant difference (P < 0.001) in TG level
compared with negative control. Groups that received AQ crude
extract (500 and 1000mg/kg/day), AQ residue of AQ crude
extract (1000mg/kg/day) and normal control showed significant
difference (P < 0.05) in BG level compared with negative control
(Table 5).
The percentage difference BG level between AQ crude extract
and AQ residue of AQ extract (1000mg/kg) and negative
control were 50.6 and 46.9, respectively. Whereas, the percentage
difference BG level between AQ crude extract and AQ residue of
AQ extract (1000mg/kg) and normal control were 3.4 and 9.0,
respectively.
DISCUSSION
This study investigated the in vivo antihypertensive effects of
different extracts of M. stenopetala (Baker f.) Cufod. Leaves
in D-Fructose (66% w/v ad libitum) induced hypertensive
male Wistar rats. In addition, the effects on lipid profile and
phytochemical screening of different extracts of M. stenopetala
(Baker f.) Cufod. Leaves were done. This is the first indepth study
to investigate the effect of different extracts of M. stenopetala
(Baker f.) Cufod. Leaves on BP.
Phytochemical Screening
Phytochemicals are non-nutritive plant chemicals which may
have some disease preventive or treatment properties. The four
solvent extracts (AQ crude, 70% EtOH crude, EtAc partition, and
AQ partition residue of AQ crude) of the fresh M. stenopetala
(Baker f.) Cufod. Leaves were screened for the presence of
different phytochemicals.
The qualitative phytochemical screening of AQ extract
showed the presence of all tested secondary metabolites. This
finding is in agreement with the study done on AQ extract
of M. oleifera (Brindha et al., 2014). And 70% EtOH extract
showed presence of all tested phytochemicals except saponins.
This finding is inline with the study done on EtOH extract of
M. oleifera (Onyekaba et al., 2013). Tannin and phytosterol were
present in all tested extracts. Saponin was present in all tested
extracts but not in 70% EtOH crude extract. Only crude extracts
showed a positive test result for alkaloids and glycosides. One of
the previous studies showed the presence of alkaloids, tannins,
and glycosides but no saponins and anthraquinones in EtOH
extract ofM. oleifera (Denen et al., 2014). Another study showed
the presence of all tested metabolites (tannin, alkaloid, saponin,
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TABLE 5 | Effect of crude extracts and solvent fractions of M. stenopetala (Baker f.) Cufod. leaves on lipid profiles (TC, BG, and TG plasma level) in
D-Fructose (66% w/v ad libitum) induced rats.
Substance administered Dose (mg/kg) Lipid Profiles
CHOL (mg/dl) GLUC (mg/dl) TG (mg/dl)
D-Fructose 66%w/w ad libitum 67.37 ± 5.87*b 142.00 ± 4.49*c 333.97 ± 32.92*a,*c
Captopril 20 63.73 ± 5.47 121.98 ± 19.20 298.23 ± 28.62*c
AQ crude 250 62.68 ± 6.00 132.83 ± 3.77*b 310.30 ± 8.09*c
500 59.17 ± 5.52 109.15 ± 3.45**a 297.33 ± 12.78*c
1000 57.75 ± 4.11 94.28 ± 2.76**c 194.53 ± 20.50**a,*a
70% EtOH crude 250 61.50 ± 6.95 141.02 ± 2.17*c 329.43 ± 39.25*c
500 58.28 ± 4.21 129.48 ± 9.39*a 297.58 ± 17.17*c
1000 57.82 ± 2.13 114.67 ± 2.73 267.38 ± 13.37*c
EtAc fraction of AQ crude 250 56.72 ± 8.84 139.17 ± 2.21*c 252.70 ± 1.95*c
500 58.22 ± 2.85 130.92 ± 4.36*a 258.55 ± 34.22*c
1000 60.72 ± 2.06 119.80 ± 3.34 317.22 ± 19.57*c
AQ fraction of AQ crude 250 57.05 ± 4.81 132.53 ± 1.75*b 215.40 ± 40.34*b
500 54.05 ± 3.93 122.15 ± 4.26 310.27 ± 20.80*c
1000 59.57 ± 4.35 96.70 ± 4.26**a 298.44 ± 7.18*c
Negative Control Distilled Water 51.20 ± 4.69**b 97.60 ± 2.89**a 56.50 ± 3.13**c,***c
Results are expressed as mean ± SEM (n = 6), *compared with normal control; **compared with negative control; ***compared to positive control.
aP < 0.05.
bP < 0.01.
cP < 0.001.
and phenol) in both EtOH and EtAc crude extract of M. oleifera
(Ojiako, 2014). On the otherhand, another study showed the
presence of all tested metabolites (flavonoid, anthraquinone,
alkaloid, saponin, terpenoid, glycoside, and tannin) in both
EtOH and AQ crude extract of M. oleifera (Nweze and Felix,
2014). The present study indicated that the fresh leaves extracts
of M. stenopetala (Baker f.) Cufod. contain different classes
of secondary metabolites. The yield obtained for secondary
metabolites of M. stenopetala (Baker f.) Cufod. leaves in the
present study was recorded to be highest in the case of AQ
crude extract followed by 70% EtOH crude, AQ residue, and
EtAc fraction of AQ crude extract in succession. The presence
of these phytochemicals gave a great potential for extracts of M.
stenopetala leaves in producing vasodilatory effect that signifies
the potential of the plant as a source of therapeutic agent.
In vivo Antihypertensive and
Antihyperlipidemic Activity
Effect on Blood Pressure
The negative control rats which received 66% w/v D-Fructose
served as hypertensive model with an average increase in
SBP (50mmHg), DBP (25mmHg), and MAP (33mmHg) from
basal BP. Whereas, positive control which were given captopril
(20mg/kg/day) with 66% w/v D-Fructose ad libitum showed the
average change in SBP (7mmHg), DBP (−1mmHg), and MAP
(2mmHg) were considered as normotensive after 15 days of
study period.
Daily oral administration of the crude extracts of
M. stenopetala (Baker f.) Cufod. significantly prevented the
increase in SBP, MAP, and DBP in 66% w/v D-Fructose ad
libitum consuming rats in a dose dependent manner. The highest
daily oral dose of AQ crude extract (1000mg/kg) significantly
prevented the increase in SBP, MAP and DBP comparable to
positive and normal control, groups that received captopril
(20mg/kg/day) and distilled water (ad libitum), respectively.
The highest dose of 70% EtOH crude extract also produced
a significant decrease in SBP, MAP, and DBP. Whereas, the
EtAc fraction and AQ residue of AQ crude extract did not
show significant decrease in SBP, MAP, and DBP, rather there
was significant rise in SBP, MAP, and DBP comparable to
that in negative control, groups that received only 66% w/v
D-Fructose ad libitum. The AQ and 70% EtOH crude extract
produced the highest dose dependent antihypertensive effect.
This effect may be attributed to the presence of alkaloids and
glycosides in crude extracts. This finding is in agreement with
the study done on alkaloids of M. oleifera leaves on isolated frog
heart (negative inotropic and chronotropic effect; Dangi et al.,
2002), on glycosides isolates of M. oleifera leaves (Faizi et al.,
1995).
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Effect on Total Cholesterol, Glucose, and Triglyceride
Plasma Levels
In this study, it was observed that the extracts decreased
TC, BG, and TG plasma levels in a dose dependent manner
indicating that they could prevent atherosclerosis. The level of
TG however, increased with the extracts. This finding is in line
with those of the previous studies carried out on antidiabetic
and antihyperglycemic activity of different solvent extracts of
M. stenopetala (Baker f.) Cufod. leaves using various models:
70% EtOH and its fractions in alloxan induced diabetic mice
(Sileshi et al., 2014), n-butanol fraction of 70% EtOH in alloxan
induced diabetic mice (Toma et al., 2012) and AQ, 70% EtOH
and n-butanol fractions in STZ induced diabetic rats (Toma
et al., 2015). The finding is also in agreement with those of the
previous studies done on antidiabetic and antihyperlipidemic
of different solvent extracts of M. oleifera leaves using various
models: AQ extract in STZ and fructose induced rats (Divi
et al., 2012), EtOH extract in STZ induced diabetic rats (Chinedu
et al., 2014), EtOH extract in hypercholesterolemic rats (Denen
et al., 2014), AQ extract in diabetic patients (Brindha et al.,
2014), and 98% EtOH extract in alloxan induced rats (Aja et al.,
2015).
In the present study, AQ crude and residue extract of
M. stenopetala (Baker f.) Cufod. showed the suppression in
BG level increment in a dose dependent manner. The highest
suppression was observed at 1000mg/kg which is comparable
with normal rats. The TC, BG and TG plasma level suppression
effect was high in groups that received AQ crude followed by
70% EtOH crude extract. The AQ crude extract (1000mg/kg)
has suppressed the TC, BG, and TC level by 87.2, 96.6, and
37.2% compared to normal control. The crude extracts showed
dose dependent suppression in TC, BG, and TG level increment
and the highest effect was observed at the maximum tested dose
(1000mg/kg/day).
CONCLUSION
This study demonstrated the in vivo antihypertensive and
antihyperlipidemic activity of the AQ and 70% EtOH crude
extracts ofM. stenopetala (Baker f.) Cufod. leaves in 66% w/v D-
Fructose induced hypertensive male Wistar rats. Further studies,
however, need to be done to confirm this using different model.
Moreover, in-depth investigations are required in order to isolate
and identify the phytoconstituents that are responsible for the
plants antihypertensive and antihyperlipidemic activity as no
prior studies have been undertaken in this regard.
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